References
- . Centers for Disease Control and Prevention. Meningitis outbreaks. 2013. http://www.cdc.gov/hai/outbreaks/meningitis.html. Accessed December 12, 2013
- . Centers for Disease Control and Prevention. Multistate fungal meningitis outbreak investigation. CDC responds to multistate outbreak of fungal meningitis and other infections. 2013. http://www.cdc.gov/hai/outbreaks/currentsituation/. Accessed December 12, 2013
- . Goldberg RA, Flynn HW Jr, Isom RF, Miller D, Gonzalez S. An outbreak of streptococcus endophthalmitis after intravitreal injection of bevacizumab. Am J Ophthalmol. 2012;153(2):204–208;e201
- . Pergolizzi JV Jr, Labhsetwar S, LeQuang JA. Compounding pharmacies: who is in charge? Pain Pract. 2013;13(3):253–257
- . US House of Representatives. H.R. 3204: Drug Quality and Security Act, 2013. https://www.govtrack.us/congress/bills/113/hr3204/text. Accessed February 2, 2014
- . Elia Aguilar, Plaintiff v INFUPHARM, LLC, South Florida Eye Associates, PA, Michel Rizo and Natalia Villate, MD, Defendants. Circuit Court of the 11th Judicial Circuit, Miami-Dade County, FL, 2011
- . American College of Obstetricians and Gynecologists, Society for Maternal-Fetal Medicine. Information Update on 17a-hydroxyprogesterone caproate (17P). April 28, 2011
- . Gudeman J, Jozwiakowski M, Chollet J, Randell M. Potential risks of pharmacy compounding. Drugs R D. 2013;13(1):1–8
- . US Food and Drug Administration. Guidance for FDA Staff and Industry. Compliance Policy Guides Manual. Pharmacy Compounding. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM124736.pdf. Accessed February 2, 2014
- . Wynkoop K. Liability and coverage for contaminated-product claims. Ophthalmic Mutual Insurance Company Opthalmic Risk Management Digest. 2012;22(4):1–7